Germany: Biotechnology Sartorius Acquires Cell Culture Specialist Xell
By acquiring Xell, Sartorius is further expanding its cell culture media business with a focus on media for gene therapies and vaccines. In this way, the Group is primarily expanding its capacities for the production of powder and liquid media.
Goettingen/Germany — The life science company Sartorius has acquired the cell culture specialist Xell, based in Bielefeld, Germany, through its subgroup Sartorius Stedim Biotech. Xell develops, produces and markets nutrient media for cell cultures, especially for the production of viral vectors used in gene therapies and vaccines. In addition, the company offers various analytical services to characterize and quantify media components and optimize media formulations.
Previously privately held, Xell employs approximately 35 people and is expected to generate revenues of approximately five million euros in 2021 with strong growth rates and a significant double-digit Ebitda margin. A very extensive and state-of-the-art capacity expansion was recently completed at the company's headquarters. The contractual partners agreed on a purchase price of around 50 million euros plus two earn-out components, which are dependent on the achievement of defined sales targets in the years 2022 to 2025.